WO 2004/041777 PCT/US2003/034002

WHAT IS CLAIMED IS:

1. A compound of the formula I:

$$R^3$$
 R^5 R^6 N N R^2 R^1 R^{10}

5

wherein:

R¹ is selected from:

hydrogen,

- C_{0-6} alkyl-Y-(C_{1-6} alkyl)-, and

10 -(C₀-6alkyl)-Y-(C₀-6alkyl)-(C₃-7cycloalkyl)-(C₀-6alkyl),

where Y is selected from:

a single bond, -O-, -S-, -SO-, -SO₂-, and -NR 10 -,

and where the alkyl and the cycloalkyl are unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

15

- (a) halo,
- (b) hydroxy,
- (c) -O-C₁₋₃alkyl, and
- (d) trifluoromethyl,
- (e) C₁₋₃alkyl,

20

- (f) -O-C₁-3alkyl,
- (g) -CO₂R⁹, wherein R⁹ is independently selected from: hydrogen, C₁₋₆ alkyl, C₅₋₆ cycloalkyl, benzyl or phenyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, C₁₋₃alkyl, C₁₋₃alkoxy and trifluoromethyl,

- (h) -CN,
- (i) heterocycle,
- (j) $-NR^9R^{10}$,
- (k) $-NR^9COR^{10}$,
- (l) $-NR^9SO_2R^{10}$, and

WO 2004/041777 PCT/US2003/034002

(m) $-CONR^9R^{10}$;

R² is selected from:

10

30

(C0-6alkyl)-phenyl and (C0-6alkyl)-heterocycle,

where the alkyl is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

- (a) halo,
- (b) hydroxy,
- (c) -O-C₁-3alkyl,
- (d) trifluoromethyl, and
 - (e) -C₁-3alkyl,

and where the phenyl and the heterocycle is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

- (a) halo,
- 15 (b) trifluoromethyl,
 - (c) trifluoromethoxy,
 - (d) hydroxy,
 - (e) C₁₋₆alkyl,
 - (f) C₃₋₇cycloalkyl,
- 20 (g) -O-C₁-6alkyl,
 - (h) -O-C3-7cycloalkyl,
 - (i) -SCF3,
 - (j) -S-C₁-6alkyl,
 - (k) -SO2-C1-6alkyl,
- 25 (l) phenyl,
 - (m) heterocycle,
 - (n) $-CO_2R^9$,
 - (o) -CN,
 - (p) $-NR^{9}R^{10}$,
 - (q) $-NR^9-SO_2-R^{10}$,
 - (r) $-SO_2-NR^9R^{10}$, and
 - (s) $-CONR^9R^{10}$;

R³ is selected from:

(C0-6alkyl)-heterocycle,

where the alkyl is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

- halo, (a)
- hydroxy, (b)
 - -O-C1-3alkyl, and (c)
 - trifluoromethyl, (d)

and where the heterocycle is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

halo, (a) 10

5

15

- trifluoromethyl, (b)
- hydroxy, (c)
- C₁-3alkyl, (d)
- -O-C1-3alkyl, (e)
- $-CO_2R^9$, **(f)**
- -CN, (g)
- -NR9R10, and (h)
- -CONR9R10; (i)
- R⁴ is selected from: 20
 - hydrogen, (a)
 - hydroxy, (b)
 - C₁-6alkyl, (c)
 - C₁₋₆alkyl-hydroxy, (d)
 - -O-C1-3alkyl, (e)
 - $-CO_2R^9$, (f)
 - -CONR9R10, and (g)
 - -CN; (h)
 - ${\rm R}^5$ and ${\rm R}^6$ are independently selected from: 30
 - hydrogen, (a)
 - hydroxy, (b)
 - C₁-6alkyl, (c)
 - C₁₋₆alkyl-hydroxy, (d)

- (e) -O-C₁-3alkyl,
- (f) oxo, and
- (g) halo;
- 5 R¹⁰ is independently selected from:

hydrogen, C₁₋₆ alkyl, benzyl, phenyl, and C₁₋₆ alkyl-C₃₋₆ cycloalkyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, C₁₋₃alkyl, C₁₋₃alkoxy and trifluoromethyl;

10

n is an integer which is 0 or 1;

and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

15 2. The compound of Claim 1 wherein R¹ is selected from: -C₁-6alkyl, -C₀-6alkyl-O-C₁-6alkyl-, -C₀-6alkyl-S-C₁-6alkyl-, and -(C₀-6alkyl)-(C₃-7cycloalkyl)-(C₀-6alkyl),

where the alkyl and the cycloalkyl are unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

20

- (a) halo,
- (b) hydroxy,
- (c) -O-C1-3alkyl,
- (d) trifluoromethyl,
- (f) C₁₋₃alkyl,
- 25 (g) -O-C₁-3alkyl,
 - (h) -CO₂R⁹, wherein R⁹ is independently selected from: hydrogen, C₁₋₆ alkyl, C₅₋₆ cycloalkyl, benzyl or phenyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, C₁₋₃alkyl, C₁₋₃alkoxy and trifluoromethyl,

- (i) -CN,
- (j) $-NR^{9}R^{10}$, and
- (k) $-CONR^9R^{10}$.
- 3. The compound of Claim 1 wherein R¹ is selected from:

	(1) -C ₁₋₆ alkyl, which is unsubstituted or substituted with 1-6 substituents where the			
	(1) -C ₁₋₆ alkyl, which is unsubstituted as substituents are independently selected from:			
	(a) halo,			
5	(b) hydroxy, (c) -O-C ₁ -3alkyl, and			
-	 (d) trifluoromethyl, (2) -C₀-6alkyl-O-C₁-6alkyl-, which is unsubstituted or substituted with 1-6 substituents where the substituents are independently selected from: 			
	(a) halo, and			
10	(b) trifluoromethyl, (3) -C ₀ -6alkyl-S-C ₁ -6alkyl-, which is unsubstituted or substituted with 1-6			
	(3) -C0_6aikyl-5-C1_bankyl , where the substituents are independently selected from:			
	(a) halo, and			
	(-)			
15	(b) trifluoromethyl, -(C3-5cycloalkyl)-(C0-6alkyl), which is unsubstituted or substituted with 1-7			
13	(4) -(C3-5cycloarky)-(C0-0das-y-) substituents where the substituents are independently selected from:			
	(a) halo,			
	(b) hydroxy,			
	(c) -O-C ₁₋₃ alkyl, and			
20	(d) trifluoromethyl.			
	4. The compound of Claim 1 wherein R ¹ is selected from:			
	(1) -CH ₃ ,			
	(2) -CH ₂ CH ₃ ,			
25	(3) -CH(CH ₃) ₂ ,			
23	(4) -CH ₂ CH ₂ CH ₃ ,			
	(5) -CH ₂ CH(CH ₃) ₂ ,			
	(6) -cyclopropyl,			
	(7) -cyclobutyl,			
30	(8) -cyclopentyl,			
50	(9) -CH2-cyclopropyl,			
	(10) -CH2-cyclobutyl,			
	(11) -CH2-cyclopentyl,			
	(12) -CH ₂ OH,			
	- 82 -			

WO 2004/041777

- -C(CH3)2(OH), (13)-C(CH2OH)(CH3)2, (14) -(OH)cyclobutyl, (15)-(OH)cyclopentyl, (16) -C(CH3)2(NHCOCH3), (17)5 -C(CO₂H)(CH₃)₂, (18) -O-CH3, (19)-O-cyclopentyl, (20)-O-CH(CH3)2, (21)-S-CH3, (22)10 -S-CF3, (23)-SO2-CH3, (24)-S-CH(CH3)2, (25)-SO2-CH(CH3)2, and (26)-NH-SO2-CH3. (27)15 The compound of Claim 1 wherein R² is selected from: 5. -(C₀₋₄alkyl)-phenyl and -(C₀₋₄alkyl)-heterocycle, where heterocycle is selected from: furanyl, imidazolyl, oxadiazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyridazinyl, pyrimidyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and triazolyl, and 20 where the alkyl is unsubstituted or substituted with 1-7 substituents where the N-oxides thereof, substituents are independently selected from:
 - and where the phenyl or heterocycle is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
 - (a) halo,
 - (b) trifluoromethyl,
 - (c) trifluoromethoxy,
 - (d) hydroxy,

halo,

hydroxy,

-O-C1-3alkyl, and

(a)

(b)

(c)

25

WO 2004/041777

5	(f) -O (g) -O (h) -S (i) -S (j) -S (k) -O (l) -I (m) -I	_3alkyl, -C1_3alkyl, -C2_3alkyl, -C1_3alkyl, -C1_3alkyl, -C2_3alkyl, -C2_3alky	
10	(0)	$ m SO_2$ -NR 9 R 10 , and $ m CONR}^9$ R 10 .	
15	6. The compound of Claim 1 wherein R ² is selected from: -(C ₀ -4alkyl)-phenyl and -(C ₀ -4alkyl)-heterocycle, where heterocycle is selected from: pyridyl, pyridazinyl, and N-oxides thereof, where the alkyl is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:		
20	(a) (b) (c) (d)	halo, hydroxy, -O-C1-3alkyl, and trifluoromethyl, phenyl or heterocycle is unsubstituted or substituted with 1-3 substituents the substituents are independently selected from:	
25	(a) (b) (c)	halo, trifluoromethyl, trifluoromethoxy, hydroxy,	
30	(d) (e) (f) (g) (h) (i)	C ₁ -3alkyl, -O-C ₁ -3alkyl, -CO ₂ -C ₁ -3alkyl, -CO ₂ H, -S-C ₁ -3alkyl,	
	(j) (k)	-SO ₂ -C ₁ -3alkyl, -SCF ₃ ,	

-NH2, (I) -NH-SO2-C1-3alkyl, and (m) -SO2-NH2. (n) The compound of Claim 1 wherein \mathbb{R}^2 is selected from: 7. 5 -CH2-phenyl and -CH2-heterocycle, where heterocycle is selected from: pyridyl, pyridazinyl, and N-oxides thereof, and where the phenyl or heterocycle is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, (a) 10 trifluoromethyl, (b) trifluoromethoxy, (c) hydroxy, (d) C₁-3alkyl, (e) -O-C1-3alkyl, (f) 15 -CO2-C1-3alkyl, (g) -CO₂H, (h) -S-C1-3alkyl, (i) -SO₂-C₁-3alkyl, (j) -SCF₃, (k) 20 -NH₂, **(l)** -NH-SO2-C1-3alkyl, and (m) -SO₂-NH₂. (n) The compound of Claim 1 wherein \mathbb{R}^2 is selected from: 8. 25 -CH2-(phenyl), (1) -CH2-(4-bromophenyl), (2) -CH2-(3-chlorophenyl), (3) -CH₂-(3,5-difluorophenyl), (4) -CH2-((2-trifluoromethyl)phenyl), (5) 30 -CH2-((3-trifluoromethyl)phenyl), (6) -CH2-((4-trifluoromethyl)phenyl), (7) -CH2-((3-trifluoromethoxy)phenyl), (8) -CH2-((3-trifluoromethylthio)phenyl),

(9)

	(10) -CH2-((3-trifluoromethoxy-5-thiomethyl)phenyl),
	wish or wethoxy-5-methoxy)pnenyi),
	(11) -CH2-((3-trifluorometriox) 5 methanesulfonyl)phenyl),
	(11) -CH2-((3-trifluoromethoxy-5-methanesulfonyl)phenyl), (12) -CH2-((3-trifluoromethoxy-5-methanesulfonyl)
	(/2 4):fluoromethoxy-5-amino)phenyi),
	OTIO ((3.trifluoromethoxy-5-aminomethanesunony))
5	- (G methoxy-5-sulfonviamino)pilenyi,
	The first time to the second that the second to the second
	(16) -CH2-((3,5-018-United of order of the company)
	(17) -CH2-((3-fluoro-5-trifluoromethyl)phenyl),
	(17) -CH ₂ ((3 Here)), (18) -CH(CH ₃)-((3,5-bis-trifluoromethyl)phenyl),
4.0	(18) -C(CH3)2-((3,5-bis-trifluoromethyl)phenyl),
10	(A (a sign-oromethyl)nyridyl).
	(a wish-aromethyl)nyridyl).
	(21) -CH2-(5-(3-timuorometry)))
	(22) -CH ₂ -(5-(3-trifluoromethyl)pyridazinyl),
	(23) -CH ₂ -(4-(2-trifluoromethyl)pyridyl-N-oxide), and
	(24) -CH ₂ -(5-(3-trifluoromethyl)pyridyl-N-oxide).
15	(27) 02-2 (
	2 . 4

The compound of Claim 1 wherein R³ is heterocycle,

where the heterocycle is selected from: imidazole, pyrimidyl, triazole or tetrazole, and where the heterocycle is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

- halo, (a)
- trifluoromethyl, (b)
- hydroxy, (c)
- C₁-3alkyl, (d)
- -O-C1-3alkyl, (e)
- -CO₂R⁹, **(**f)
- -CN, (g)
- -NR9R10, and (h)
- -CONR9R10. (i)

30

20

25

The compound of Claim 1 wherein \mathbb{R}^3 is heterocycle,

where the heterocycle is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from:

halo, (a)

WO 2004/041777 PCT/US2003/034002

- (c) hydroxy,
- (d) C₁₋₃alkyl,
- (e) -O-C1-3alkyl, and
- (f) $-CO_2R^9$.

5

- 11. The compound of Claim 1 wherein R³ is selected from: imidazole, pyrimidyl, triazole or tetrazole.
 - 12. The compound of Claim 1 wherein R³ is selected from:

10

- 13. The compound of Claim 1 wherein R⁴ is selected from:
- (a) hydrogen,
- (b) hydroxy,
- (c) -CO₂H,
- (d) -CO2C1-6alkyl,
- (e) -CN.
- 14. The compound of Claim 1 wherein R⁴ is hydrogram.

WO 2004/041777

The compound of Claim 1 wherein \mathbb{R}^5 and \mathbb{R}^6 are independently selected 15. from: hydrogen, (a) hydroxy, (b) -CH3, (c) 5 -O-CH3, and (d) oxo. (e) The compound of Claim 1 wherein \mathbb{R}^5 is independently selected from: 16. hydrogen, (a) 10 -CH3, and (b) -O-CH3. (c)

17. A compound which is selected from the group consisting of the title compounds of the Examples, and pharmaceutically acceptable salts and individual diastereomers

thereof.

18. A pharmaceutical composition which comprises an inert carrier and a compound of Claim 1.

15

20

25

19. A method for modulation of chemokine receptor activity in a mammal in need thereof which comprises the administration of an effective amount of the compound of Claim 1.

20. A method for treating, ameliorating or controlling an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim 1.

21. A method for reducing the risk of an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim 1.

22. A method for treating, ameliorating or controlling rheumatoid arthritis which comprises administering to a patient in need thereof an effective amount of the compound of Claim 1.